DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

Muscarinic receptors are involved with neurotransmission ... Most drugs developed to treat schizophrenia to date target dopamine pathways. The hope is that NBI-1117568 will have a two-pronged ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Developed by Karuna Therapeutics and later acquired by Bristol Myers Squibb, it targets the cholinergic system through muscarinic receptors, differing from ... antibody that simultaneously targets two ...

While Cobenfy proved the potential of targeting the muscarinic pathway in schizophrenia ... The difference might lay in the M1 receptor, Stifel analysts suggested in November. While Cobenfy acts on ...

Several pathways to involvement of the olfactory network are ... a powerful inhibitor of acetylcholinesterase that causes seizures via stimulation of muscarinic and nicotinic receptors, pre-lesioning ...

University of California has described tropane derivatives acting as 5-HT2 and muscarinic receptor ligands reported to be useful for the treatment of psychiatric disorders, depression, ...

The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study. Blocking ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...